DG SANCO: IMCA II – Indicators for Monitoring COPD and Asthma in the EU

Project title DG SANCO: IMCA II - Indicators for Monitoring COPD and Asthma in the EU
Funding Leader organisation: Fundació IMIMCDr Aiguader 88, 08003 Barcelona, SPAIN

Program: DG SANCO Agreement No.: (no. 2005121)

Contact Person: Enric DURAN, Tel: +34932211009 / Fax:+34932213237, E-mail: e.duran@imim.es

Duration 15/12/2006-14/04/2010
Project leader...........

(National coordinator)

Dr. Iveta Rajnicova-Nagyova
Research team (KISH) Dr. Iveta Rajnicova-Nagyova, Dr. Zuzana Katreniakova, MD
Associated beneficiaries - Prestacions d’Assistència Mèdica S - Spain - Hospital Clínic i Provincial de Barcelona - Spain - Medizinische Universitat Wien- Austria - Hvidovre Hospital- Denmark - Kansanterveyslaitos - National Public Health Institute - Finland - Université de la Méditerranée Aix Marseille II - France - Universitatsklinikum Ulm - Germany - PNOE Asthma Research Foundation - Greece - University of Crete - Greece - Research Institute for a Tobacco Free Society (RIFTRS) - Ireland - Consiglio Nazionale delle Ricerche, Institute of Clinical Physiology - Italy - Azienda Sanitaria Locale Roma, Dipartimento d’Epidemiologia - Italy - Centre Hospitalier de Luxembourg - Luxembourg - Rijksinstituut voor Volksgezondheid en Milieu (RIVM) - the Netherlands - Sociedade Portuguesa de Alergologia e Imunologia Clinica - Portugal- Uppsala Universitet - Sweden - Imperial College of Science, Technology and Medicine - United Kingdom - Innovest AS - Norway - Association Asthma - Bulgaria - Cyprus International Institute for the Environmental and Public Health - Cyprus - Czech Initiative for Asthma - Czech Republic - Sihtasutus Tartu Ulikooli Kliinikum - Tartu University Hospital - Estonia - Fodor Jozsef National Centre For Public Health - Hungary - National Tuberculosis and Long Diseases Research Institute (IGICHP) - Poland - Landspitali University Hospital - Iceland - PJ Safarik University, Faculty of Medicine, KISH - Slovak Republic - University Clinic of Respiratory and Allergic Diseases - Slovenia - University of Medicine and Pharmacy - Romania - Health Department of Catalonia - Spain
Framework European Comission, DG SANCO
Total cost/Subsidy from the Commission 2.729.034 € / 1.637.420 €


Improving information and knowledge for the development of public health


Area of activity

Developing mechanisms for the reporting and analysis of health issues and producing public health reports


Main findings



Summary Asthma and COPD are major chronic disease that have an important impact on quality of life of individuals suffering the disease and also have important consequences into social and health care cost. The information available today either to prevent risk factors or to improve clinical management and outcomes is still very limited. The aim of this proposal is to extend the work on indicators already carried out by the IMCA I project by collecting or using already available data and producing reports/papers on all groups of indicators recommended by the project (mortality, prevalence, risk factors, clinical management/health services and outcomes). We will collect routine data on mortality and hospital discharges to estimate the indicators defined by the IMCA I project (for a period of ten years) for all countries involved in the project and to analyze geographical variations and time trends on these indicators. We will also collect data on health care, human resources and health care utilization costs to estimate the indicators defined by the IMCA I project. Available data from completed European-wide research projects (ECRHS and ISAAC) will be used to describe the most relevant indicators. Available data from completed European-wide research projects (ECRHS and ISAAC) will be used to describe the most relevant indicators.

The project also aim extend the work of IMCA I project by developing a module of COPD and asthma to be incorporated to health examination surveys and testing its feasibility and pilot performance in four selected small a large sample of geographical areas of Spain, Italy, Sweden and Germany. in Europe. We will explore the use of a group of essential measurements of respiratory health and morbidity to be introduced in future HES using innovative technological methods (sensors) to carry out measurements, validate and transmit the data (fieldwork online) and the use of a Telemedicine Network (GBT-UPM) to provide training and support online to the fieldworkers. This technology that will be used has been developed by MOTOROLAHEALTH. A new questionnaire "module" based in previously validated questionnaires by which the information required to estimate the IMCA I indicators (recommended to be collected by survey) can be obtained will be developed. The project will explore the feasibility of taking a blood sample at home in the context of a HES to measure the relevant indicators on allergy (IgE and specific IgE), obtain DNA samplesobtention and other ad hoc determinations.